title: Plasma levels of tumor necrosis factor-alpha in patients with visceral leishmaniasis (Kala-azar). Association with activity of the disease and clinical remission following antimonial therapy.
abstract: Evaluation of TNF-alpha in patients with Kala-azar has drawn increasing interest due to its regulatory role on the immune system, in addition to its cachetizing activity. The objective of this study was to examine the association between plasma levels of TNF-alpha, measured by immunoreactivity (ELISA) and bioactivity (cytotoxicity assay with L-929 cells), and clinical manifestations of visceral leishmaniasis. Plasma samples from 19 patients with Kala-azar were obtained before, during and at the end of antimonial therapy. TNF-alpha determinations was done by using the cytotoxicity assay (all patients) and the enzyme-linked immunoassay (ELISA-14 patients). A discrepancy between results obtained by ELISA and cytotoxicity assay was observed. Levels of circulating TNF-alpha, assessed by ELISA, were higher in patients than in healthy controls, and declined significantly with improvement in clinical and laboratory parameters. Plasma levels before treatment were 124.7 +/- 93.3 pg/ml (mean +/- SD) and were higher than at the end of therapy 13.9 +/- 25.1 pg/ml (mean +/- SD) (p = 0.001). In contrast, plasma levels of TNF-alpha evaluated by cytotoxicity assay did not follow a predicted course during follow-up. Lysis, in this case, might be not totally attributed to TNF-alpha. The discrepancy might be attributed to the presence of factor(s) known to influence the release and activity of TNF-alpha.
authors.affiliation: Division of Infectious Diseases, Escola Paulista de Medicina, São Paulo, Brasil.
authors.forename: R
authors.initials: R
authors.lastname: Salomão
authors.forename: A
authors.initials: A
authors.lastname: Castelo Filho
authors.forename: I M
authors.initials: IM
authors.lastname: de Medeiros
authors.forename: M A
authors.initials: MA
authors.lastname: Sicolo
mesh_terms: D000981:Antiprotozoal Agents / Q000627:therapeutic use; D006801:Humans; D007898:Leishmaniasis, Visceral / Q000097:blood* / Q000188:drug therapy; D008536:Meglumine / Q000627:therapeutic use; D000077485:Meglumine Antimoniate; D009942:Organometallic Compounds / Q000627:therapeutic use; D012074:Remission Induction; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis*
chemical_list: D000981:Antiprotozoal Agents; D009942:Organometallic Compounds; D014409:Tumor Necrosis Factor-alpha; D008536:Meglumine; D000077485:Meglumine Antimoniate